Skip to main content
. 2017 Oct 10;8(59):99990–100001. doi: 10.18632/oncotarget.21725

Figure 4. A set of four salivary miRNAs that can be used in discriminating healthy controls from the early stage (Stages I&II) of HPV-negative HNSCC patients.

Figure 4

Significant differences are *P<0.05 and ***P<0.001.